Influenza tetravalent vaccines in national immunization programs for Latin-American countries
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
AuthorsMacías Hernández, Alejandro E.
Santos, Fortino Solórzano
Aguilar Velasco, Hugo M.
Ávila Agüero, María L.
Rubio, Fernando Bazzino
Junqueira Bellei, Nancy C.
Bonvehí, Pablo E.
Del Castillo, José Brea
Leguizamón, Héctor Castro
Allan Santos Domingues, Carla M.
García García, María D.L.
Trujillo, Darío Londoño
Lópe, Pío López
De León Rosales, Samuel Ponce
Cervantes Powell, Patricia G.
Suárez Ognio, Luis A.N.
Ruiz-Palacios y Santos, Guillermo M.
Tetravalent influenza vaccine
Cost effectiveness analysis
MetadataShow full item record
Other TitlesVacuna tetravalente de influenza en los programas nacionales de inmunización para los países de América Latina
JournalEnfermedades Infecciosas y Microbiologia
AbstractSince 2012-2013 influenza season, World Health Organization (who) recommends the formulation of tetravalent vaccines. Globally, many countries already use tetravalent vaccines in their national immunization programs, while in Latin America only a small number. Two Influenza b lineages co-circulate, their epidemiological behavior is unpredictable. On average they represent 22.6% of influenza cases and more than 50% in predominant seasons. The lack of concordance between recommended and circulating strains was 25 and 32% in the 2010-2017 and 2000-2013 seasons, respectively. There are no clinical differences between influenza A and B. It occurs more frequently from five to 19 years of age. Influenza b has a higher proportion of attributable deaths than influenza a (1.1 vs. 0.4%), or 2.65 (95% ci 1.18-5.94). A greater number of hospitalizations when the strains mismatch (46.3 vs. 28.5%; p <.0001). Different evaluations have demonstrated its cost effectiveness. The compilation of this information supports the use of quadrivalent vaccines in Latin American countries.
Attribution-NonCommercial-ShareAlike 4.0 International
The following license files are associated with this item:
- Creative Commons
Showing items related by title, author, creator and subject.
Un nuevo virus A/H1N1, una nueva pandemia: Influenza un riesgo permanente para una humanidad globalizadaOsores Plenge, Fernando; Gómez Benavides, Jorge; Suárez Ognio, Luis; Cabezas Sánchez, César; Alave Rosas, Jorge; Maguiña Vargas, Ciro (Colegio Médico del Perú, 2014-07-16)Influenza is a highly contagious disease. There are some historical descriptions of this condition by ancient Greek physicians, and the etiological agents have been known only for the last eight decades. The causative agent is the influenza virus, which has three main types: A, B, and C. Type A is capable of circulating within many different biological reservoirs, including humans, swine, and birds. It also has high genetic variability, which allows it to have minor antigenic drifts or mutations which are responsible of epidemics in humans. Sometimes changes are quite marked, leading to pandemics. In a globalized world, with more than 6 billion inhabitants, with many social inequities and evident climate changes, influenza viruses are a permanent risk for mankind. Clinical features for the different viral subtypes may vary from subtle infections to full blown and severe, life-threatening forms. Event with the great advances in diagnostics and immunization, the manufacture and distribution of new diagnostic kits may take some time, and new vaccines are not always readily available. Specific therapies against influenza are not well developed. There are two groups of drugs, the so called adamantane derivatives, such as amantadine and rimantadine, and the neuraminidase inhibitors, such as oseltamivir and zanamivir. Most vulnerable areas for the new flu pandemics include developing countries, particularly the poorest ones, so that the greatest effort must be made for helping these areas.Acceso abierto
Niños hospitalizados con neumonía por influenza AH1N11/2009 pandémico en un hospital de referencia de Perú.Miranda-Choque, Edwin; Ramírez, Carlos; Candela-Herrera, Jorge; Díaz, Javier; Fernández, Ana; Kolevic, Lenka; Segura, Eddy R.; Farfán-Ramos, Sonia (Instituto Nacional de Salud (INS), 2014-03-25)ObjectiveTo determine the clinical and demographic characteristics of pneumonia with influenza virus AH1N1/2009 pandemic at the National Institute of Child. Methods. Retrospective case series in children hospitalized for influenza pneumonia pandemic AH1N1/2009 in a pediatric hospital. Reviewed the medical records between the months of June to September 2009. All cases had virological confirmation, we describe the clinical characteristics and conditions of severity. Results. A total of 74 children of pneumonia with influenza virus AH1N1/2009 pandemic (NVIp), of those 50 were community acquire pneumonia viral (NACv) and 24 pneumonia nosocomial viral (NNv), 16 required mechanical ventilation. 12 died, all had preexisting factors. NN cases showed statistical association with mortality. The most frequent factors were malnutrition, respiratory infections, congenital heart disease and neurological deficits In NACv cases the children under 6 years accounted for 72% (36/50). The median disease duration was 5 days. The most frequent symptoms were fever, cough, runny nose. Received oseltamivir 82%. The chest radiograph 48% of cases showed patchy infiltrates and 44% interstitial infiltrate on chest radiograph. Protein c reactive (CRP) more than 10mg / L was significantly associated with respiratory failure (p <0.05). Conclusions. Cases of NN found who had more mortality, even those who had the highest PCR and those with preexisting condition.Acceso abierto
Prevalencia de Haemophilus influenzae en lactantes hospitalizados menores de 1 año en PerúUniversidad Peruana de Ciencias Aplicadas (UPC) (Asociación Panamericana de Infectología, 2015-08-13)Las infecciones respiratorias agudas (IRAs) constituyen una de las cinco primeras causas de morbilidad y mortalidad a nivel mundial. Una bacteria causante de infecciones respiratorias agudas, principalmente en niños menores de 5 años es Haemophilus influenzae tipo b. “Se estima que provoca por lo menos tres millones de casos de enfermedad grave al año y alrededor de 86.000 de funciones, la mayor parte se registra en países en desarrollo”.El objetivo fue identificar Haemophilus influenzae tipo b en lactantes menores de 1año hospitalizados con diagnóstico de infección respiratoria aguda y presencia de tos coqueluchoide.Acceso abierto